These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 32102342)

  • 1. Monitoring Immune Responses in Neuroblastoma Patients during Therapy.
    Szanto CL; Cornel AM; Vijver SV; Nierkens S
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32102342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma.
    Mao C; Poimenidou M; Craig BT
    Cancers (Basel); 2024 Aug; 16(16):. PubMed ID: 39199637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
    Ploessl C; Pan A; Maples KT; Lowe DK
    Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
    Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
    Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma.
    Szanto CL; Cornel AM; Tamminga SM; Delemarre EM; de Koning CCH; van den Beemt DAMH; Dunnebach E; Tas ML; Dierselhuis MP; Tytgat LGAM; van Noesel MM; Kraal KCJM; Boelens JJ; Huitema ADR; Nierkens S
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33926057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma.
    Voeller J; Sondel PM
    J Pediatr Hematol Oncol; 2019 Apr; 41(3):163-169. PubMed ID: 30897608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma.
    Barry WE; Jackson JR; Asuelime GE; Wu HW; Sun J; Wan Z; Malvar J; Sheard MA; Wang L; Seeger RC; Kim ES
    Clin Cancer Res; 2019 Jan; 25(1):325-333. PubMed ID: 30232225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients.
    Blom T; Lurvink R; Aleven L; Mensink M; Wolfs T; Dierselhuis M; van Eijkelenburg N; Kraal K; van Noesel M; van Grotel M; Tytgat G
    Front Oncol; 2020; 10():601076. PubMed ID: 33680926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma.
    Kroesen M; Büll C; Gielen PR; Brok IC; Armandari I; Wassink M; Looman MW; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
    Oncoimmunology; 2016 Jun; 5(6):e1164919. PubMed ID: 27471639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.
    Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A
    J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
    Mora J
    Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.
    Ozkaynak MF; Gilman AL; London WB; Naranjo A; Diccianni MB; Tenney SC; Smith M; Messer KS; Seeger R; Reynolds CP; Smith LM; Shulkin BL; Parisi M; Maris JM; Park JR; Sondel PM; Yu AL
    Front Immunol; 2018; 9():1355. PubMed ID: 29967609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.
    Secola R; Marachelian A; Cohn SL; Toy B; Neville K; Granger M; Brentlinger A; Martin G
    J Pediatr Oncol Nurs; 2017; 34(3):160-172. PubMed ID: 28061552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
    Greenwood KL; Foster JH
    Expert Opin Drug Saf; 2018 Dec; 17(12):1257-1262. PubMed ID: 30433831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy.
    Nassin ML; Nicolaou E; Gurbuxani S; Cohn SL; Cunningham JM; LaBelle JL
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):452-459. PubMed ID: 29191664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
    Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
    McGinty L; Kolesar J
    Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance.
    Barone G; Barry A; Bautista F; Brichard B; Defachelles AS; Herd F; Manzitti C; Reinhardt D; Rubio PM; Wieczorek A; van Noesel MM
    Paediatr Drugs; 2021 Nov; 23(6):537-548. PubMed ID: 34541620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis.
    Tas ML; Dootjes LW; Fiocco M; de Krijger RR; Dierselhuis MP; van Eijkelenburg NKA; van Grotel M; Kraal KCJM; Peek AML; Tytgat GAM; van Noesel MM
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.